---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109821"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T22:03:37.806873+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q3 2025 cash $7.5M; raises $8M post-quarter, extends runway into Q1 2027

## Summary
- Cash and equivalents $7.5M at Sep 30; subsequent raises bring to $15.5M at Nov 10, funding ops into Q1 2027.
- Q3 R&D expense $2.6M (-7% YoY); G&A $1.9M (-18% YoY); workforce reduction implemented Sep 30.
- VIRAGE Phase 2b data for VCN-01 in metastatic PDAC presented at ESMO; planning Phase 3 discussions with EMA/FDA.
- Preclinical data for next-gen oncolytic virus VCN-12 showed improved cell killing and anti-tumor immunity vs VCN-01.
- Retinoblastoma Phase 2/3 trial design in progress; regulatory discussion expected H1 2026.

## SEC filing metadata
- accession: 0001104659-25-109821
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/0001104659-25-109821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/tm2530928d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109821
- JSON: https://secwatch.observer/filing/0001104659-25-109821.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.